Media headlines about Intermolecular (NASDAQ:IMI) have trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intermolecular earned a news impact score of 0.21 on Accern’s scale. Accern also assigned press coverage about the semiconductor company an impact score of 45.8966151436059 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Separately, ValuEngine raised Intermolecular from a “strong sell” rating to a “sell” rating in a report on Monday, August 7th.
Shares of Intermolecular (NASDAQ:IMI) traded up $0.01 during trading on Tuesday, reaching $1.15. The company’s stock had a trading volume of 1,300 shares, compared to its average volume of 39,167. Intermolecular has a 1-year low of $0.80 and a 1-year high of $1.20.
In related news, major shareholder Lloyd I. Miller III purchased 34,109 shares of the firm’s stock in a transaction on Friday, September 1st. The shares were acquired at an average cost of $0.86 per share, with a total value of $29,333.74. Following the purchase, the insider now directly owns 70,368 shares of the company’s stock, valued at $60,516.48. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders acquired a total of 38,930 shares of company stock worth $33,480 over the last ninety days. Insiders own 45.40% of the company’s stock.
Intermolecular Company Profile
Intermolecular, Inc provides thin film solutions. The Company’s high productivity combinatorial (HPC) platform, which consists of its tempus processing tools, its automated characterization methods, and its Informatics analysis software, is purpose-built for research and development (R&D) using combinatorial process systems.
Receive News & Ratings for Intermolecular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intermolecular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.